📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
GHRH (1–29) Analogue Growth Hormone Releasing

Sermorelin

GHRH (1–29) · Geref · Growth Hormone-Releasing Factor 1–29

"The smarter way to raise growth hormone. Rather than injecting the hormone itself, Sermorelin tells your pituitary to make more of its own — regulated by the body's own feedback system, impossible to overdose."

Type
29 amino acid GHRH fragment
Half-life
11–12 minutes
Status
UK: not illegal to buy or possess · WADA: prohibited at all times · US FDA: approved 1997 (Geref) · brand discontinued 2008 · available via compounding pharmacies
Mechanism
Pituitary GHRH receptor agonist · endogenous GH release
Protocol summary
Community dose
100–500 mcg pre-bed SubQ
Route
SubQ injection (nightly)
Cycle
3–6 months on, off-cycles vary
Community-reported
100–500 mcg SubQ pre-bed · daily before sleep
Often stacked with Ipamorelin for synergistic GH release
How we read the evidence
GHRH(1-29) — the founder GHRH analog · originally FDA-approved (Geref) for paediatric GHD · withdrawn 2008 for commercial reasons · superseded by Mod-GRF and tesamorelin
Animal evidence

Substantial preclinical foundation. Sermorelin acetate is the synthetic 29-amino-acid N-terminal fragment of human GHRH — the shortest fully functional GHRH sequence. Mechanism: agonism of GHRH receptors on pituitary somatotrophs, triggering pulsatile GH release without significant effect on prolactin, LH, FSH, insulin, cortisol, glucose, glucagon, or thyroid hormones. Pharmacokinetics: peak plasma concentrations 5–20 minutes after SubQ administration, half-life 11–12 minutes (very short). Decades of preclinical work informed the development of subsequent GHRH analogs (Mod-GRF, CJC-1295, tesamorelin) — sermorelin is the founder compound from which the modern class derives.

Community & clinical practice

Community protocols typically use 100–500 mcg SubQ once daily before bedtime on empty stomach — the bedtime dose synergises with the natural nocturnal GH surge. Some protocols pair with a GHRP (ipamorelin most commonly) for synergistic GH pulse. Cycle 8–16 weeks then break 4 weeks. The short half-life means each injection produces a discrete GH pulse rather than continuous elevation — this is mechanistically appropriate (mimics physiological pulsatile GHRH release) but requires precise timing. Most users have migrated to Mod-GRF (CJC-1295 no-DAC) for the longer half-life (~30 min vs 11–12 min) which makes once-daily dosing more practical without losing the pulsatile pattern.

Human trial data

Substantial historical Phase 3 evidence in paediatric growth hormone deficiency. Sermorelin received FDA approval as a diagnostic agent (Geref Diagnostic, 0.05 mg/amp, 1990) at 1 µg/kg single IV dose for adult GHD assessment, and as paediatric GHD treatment (Geref Pediatric, 0.5 and 1.0 mg/vial, 1997) at 30 µg/kg/day SubQ. 6-month treatment increased GH release and growth velocity in GH-deficient children; 36-month data also supported sustained efficacy. Off-label adult indications (muscle wasting in elderly with GH insufficiency, HIV lipodystrophy, cognitive impairment) showed promising preliminary data but were not pursued through formal Phase 3 development. Smaller trials exist in adults but lack the sample size and rigour of paediatric data.

Regulatory status

Originally FDA-approved (Geref) from 1990–2008. EMD Serono notified FDA in 2008 of voluntary discontinuation for commercial reasons (not safety or efficacy concerns) — FDA confirmed in 2013 that withdrawal was not for safety/effectiveness reasons, allowing potential ANDA approvals. Currently no FDA-approved branded sermorelin product exists; available via compounding pharmacies for off-label adult use. Compounded versions are not FDA-approved and don't undergo FDA review for quality. WADA-banned for tested athletes. Adult use is off-label — formal FDA approval was for paediatric GHD only. Common side effect: self-limited transient injection-site pain/redness/swelling (~16% in trials).

Convergence

Sermorelin is the founder GHRH analog and was the original FDA-approved member of this class — withdrawn for commercial rather than safety reasons. The mechanism is well-validated, the historical paediatric GHD evidence base is solid, but the compound has been functionally superseded by Mod-GRF (longer half-life, easier dosing) and tesamorelin (longer half-life, current FDA approval for HIV lipodystrophy). Standard community protocol: 100–500 mcg SubQ pre-bed, 8–16 weeks on / 4 off. Pep IQ flags this honestly: legitimate compound with real historical clinical pedigree, but Mod-GRF (paired with ipamorelin) is the cleaner modern choice for most use cases. Sermorelin remains a reasonable budget option — typically cheaper than tesamorelin, with the same fundamental mechanism — but most users will be better served by Mod-GRF.

Origin & Background

The Pituitary's own signal

Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone (GHRH) — the shortest fragment that retains full biological activity. Your hypothalamus produces GHRH naturally to signal the pituitary gland to release growth hormone in pulsatile bursts. Sermorelin mimics that signal precisely.

It was originally developed as a diagnostic tool in the 1980s to test pituitary GH reserve, then approved by the FDA in 1997 under the brand name Geref for the treatment of idiopathic growth hormone deficiency in children with growth failure. It was also approved for GH stimulation testing. The manufacturer, EMD Serono, voluntarily discontinued production in 2008 — not for safety or efficacy reasons, but due to manufacturing supply difficulties with the active ingredient.

That discontinuation opened a regulatory grey area that still exists. Sermorelin can no longer be purchased as an FDA-approved branded product, but it has not been removed from approved status. Compounding pharmacies can legally produce it, and physicians can prescribe it off-label. In the anti-ageing and functional medicine world, it became the go-to alternative to exogenous recombinant human growth hormone (rhGH).

The key distinction from rhGH: Sermorelin works one step up the hormonal chain. Rather than bypassing the pituitary by injecting growth hormone directly, it signals the pituitary to produce its own GH — maintaining the body's natural pulsatile rhythm and remaining subject to somatostatin feedback. This makes overdose physiologically impossible in a way that rhGH is not.

Science & Mechanism

How Sermorelin works

Mechanism of Action

1
GHRHR binding: Sermorelin binds to growth hormone-releasing hormone receptors (GHRHR) on pituitary somatotroph cells, activating Gs protein and adenylate cyclase, raising intracellular cAMP.
2
GH release: cAMP rise triggers calcium influx and GH vesicle exocytosis — growth hormone is released in a pulse mirroring natural physiology rather than the constant level produced by rhGH injections.
3
Feedback regulation: Somatostatin from the hypothalamus provides negative feedback, preventing GH from rising beyond physiological limits. This is the safety mechanism absent from direct rhGH therapy.
4
Pituitary support: Sustained sermorelin stimulation upregulates GH gene transcription, increasing pituitary reserve — it may actually preserve or restore pituitary function rather than causing the suppression seen with exogenous GH.
5
IGF-1 downstream: GH released from the pituitary travels to the liver and stimulates IGF-1 production — the downstream mediator responsible for most of GH's anabolic, lipolytic and regenerative effects.

The somatostatin feedback loop is what separates sermorelin from rhGH in terms of risk profile. When you inject rhGH, you are bypassing the entire regulatory system and forcing supraphysiological IGF-1 production. With sermorelin, the body's own control mechanisms remain intact — somatostatin prevents GH from rising beyond what the body permits, and the pulsatile release pattern is maintained.

GHRH naturally declines with age — this is a primary driver of the age-related fall in GH and IGF-1. Corpas et al. (1992) demonstrated that twice-daily GHRH injections in elderly men reversed age-related reductions in GH and IGF-1, restoring them toward younger levels. A 5-month randomised controlled trial by Khorram et al. (1997) in adults aged 55–71 showed significant improvements in body composition alongside hormonal restoration.

Benefits & Evidence

What the data shows

💤
Sleep quality improvement
GH is released primarily during slow-wave sleep — and sermorelin appears to deepen slow-wave sleep in a positive feedback loop. Multiple users and practitioners report this as the first and most consistent effect. GH increases slow-wave sleep; better slow-wave sleep increases GH.
● Moderate clinical evidence
🏋️
Body composition improvements
RCTs in older adults with GH insufficiency demonstrate increased lean mass and reduced fat mass, particularly visceral fat. Effects emerge at 3–6 months and require continuation. Corpas (1992) and Khorram (1997) trials showed significant lean/fat ratio improvements.
● Moderate — adult RCT data exists
⚡
Energy, mood and cognitive function
GH insufficiency in adults produces fatigue, low mood and cognitive fog. Restoring GH/IGF-1 toward younger levels addresses these downstream. Functional medicine practitioners report this as highly consistent in patients with confirmed GH decline.
● Moderate — via GH/IGF-1 restoration
🔁
Exercise recovery
IGF-1 driven by sermorelin accelerates protein synthesis and tissue repair post-exercise. Most notable in those over 40 with established GH decline. Not a performance-enhancing drug in the rhGH sense — more a restoration of normal recovery capacity.
● Moderate — indirect via IGF-1
🧠
Pituitary preservation
Uniquely, sermorelin may actually preserve and partially restore pituitary GH-secreting function rather than suppressing it. This is the opposite of what exogenous GH does. Long-term benefit that has no equivalent in direct GH replacement.
● Limited — mechanistic evidence only
Things to know

Risks & considerations

🛡️
Generally well-tolerated. Sermorelin has a strong safety record from its FDA approval period and subsequent compounding use. The somatostatin feedback mechanism provides an intrinsic safety ceiling that exogenous GH lacks. No serious adverse events were identified during clinical development.
Mild
Injection site reactions — transient redness, itching or swelling at the SubQ injection site. Common, self-resolving.
Mild
Flushing, headache, nausea — reported acutely after injection in some users. Usually diminishes after first few weeks.
Mild
Acute prolactin, FSH and LH rises — sermorelin may produce small transient rises in these hormones unlike pure GHRH, though effects appear clinically insignificant in published data.
Moderate
Water retention and joint discomfort — via elevated IGF-1, similar to but less pronounced than rhGH. Dose-dependent, more common at higher doses.
Moderate
IGF-1 elevation uncertainty — while regulated by feedback, IGF-1 levels should still be monitored. Long-term elevated IGF-1 has theoretical associations with cell proliferation that require ongoing monitoring.
Serious
Contraindicated in active malignancy — GH axis stimulation is contraindicated in anyone with a history of active cancer. Do not use without oncological clearance if any cancer history exists.

⚠ Key Warnings

Monitor IGF-1 levels before starting and every 3–6 months during use. Keep IGF-1 within age-appropriate reference ranges.
Sermorelin is WADA-prohibited — prohibited at all times for competitive athletes.
The commercial product no longer exists. Only compounded sermorelin is available. Quality varies by pharmacy — use accredited compounding pharmacies (PCAB accredited).
Effects are gradual — full results typically require 3–6 months of consistent use. Stopping early is the most common reason for disappointing outcomes.
Do not combine with exogenous rhGH — this defeats the purpose of using a regulated secretagogue and increases IGF-1 beyond physiological limits.